Group 1 - The company's stock price has experienced an abnormal fluctuation, with a cumulative increase of 30% over three consecutive trading days (July 17, July 18, and July 21, 2025) [1] - Most of the company's self-developed new drug projects are currently in various stages of preclinical development, indicating significant uncertainty in their progress [1] - There is a major uncertainty regarding the potential for external transfer of these drug projects in the future [1]